At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)
In Brief
A Early Phase 1 clinical trial evaluating 3 mg Melatonin and 5 mg Melatonin for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this study will support the rationale and be a prelude to a larger trial which can focus on clinical efficacy of melatonin therapy outcomes.
Study Details
Timeline
Interventions
3 mg melatonin once each day
5 mg Melatonin once each day